Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,036.00
Bid: 12,036.00
Ask: 12,038.00
Change: 12.00 (0.10%)
Spread: 2.00 (0.017%)
Open: 11,950.00
High: 12,142.00
Low: 11,944.00
Prev. Close: 12,024.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TOP NEWS: Officials Investigate UK Strains Showing Worrying Mutation

Tue, 02nd Feb 2021 17:26

(Alliance News) - Public Health England is investigating strains of coronavirus in the UK which have developed a mutation that has been worrying scientists.

Eleven cases in the Bristol area have been identified as the variant that originally arose in Kent but are now showing the E484K mutation.

A cluster of 32 cases in Liverpool also have the same mutation but relate to the original strain of coronavirus that has been around since the start of the pandemic.

The South African variant – which also shows the mutation – is under investigation in at least eight postcode areas of England where cases not linked to travel have been found.

A PHE spokesman said: "PHE is monitoring the situation closely and all necessary public health interventions are being undertaken, including enhanced contact tracing and control measures."

The E484K mutation has been shown to reduce the effectiveness of vaccines in preventing people contracting Covid-19.

However, public health experts believe current vaccines will still be effective against strains with the mutation, although at a lower level, and are good at preventing severe disease.

Earlier, Health Secretary Matt Hancock said testing was now under way in postcode areas affected by the mutation, alongside eight postcode areas affected by the South African variant.

Speaking in the Commons, Hancock said the government is working closely with pharmaceutical firms in case vaccines need to be tweaked to accommodate new variants.

He said: "We're working with pharmaceutical companies and with the scientists to understand both whether the such modifications are needed, where they are needed, and how they can be brought to use on the frontline as quickly and safely as possible.

"This is obviously a very important consideration given the new variants that we've seen.

"And we have confidence that modifications to vaccines, should they be necessary in large scale, will be available more quickly than the original vaccines.

"And just as we did first time round, when we got in there early and we bought at risk, so we are having exactly the same conversations right now with the pharmaceutical companies to make sure that we are right at the front of this one."

Hancock told MPs that the aim of community testing for the South African variant – currently targeting around 80,000 people in eight postcode areas – is to "stop its spread altogether".

He said: "As with the variant first identified here in the UK, there is currently no evidence to suggest it is any more severe but we have to come down on it hard.

"Our mission must be to stop its spread altogether and break those chains of transmission."

Regarding the E484K mutation seen in the Kent variant, Jonathan Stoye, from the Francis Crick Institute, said the PHE report suggests the UK variant is now independently acquiring the E484K change.

"From a virological standpoint, appearance of new variants by mutation during replication cannot be considered surprising," he added.

"Whether this change will provide significant growth advantages for the novel virus causing it to predominate remains to be seen."

Julian Tang, honorary associate professor at the University of Leicester, described the finding as "a worrying development, though not entirely unexpected".

He said it is important that people follow lockdown rules to prevent opportunities for the virus to mutate further, suggesting that allowing spread could provide a "melting pot" for different emerging variants.

"We really need to reduce our contact rates to reduce the opportunities for viral spread (and) replication to reduce the speed with which these different virus variants can evolve," he added.

Clinical trials for two coronavirus vaccines – Novavax Inc and Johnson & Johnson – have shown the jabs offer some protection against variants with the E484K mutation.

However, they are less effective than against the variant that has been around since the start of the pandemic.

Laboratory studies also suggest vaccines developed by Moderna Inc and Pfizer Inc/BioNtech SE could work against variants, while variant checks against the Oxford University/AstraZeneca vaccine are ongoing.

Earlier, Andrew Hayward, professor of infectious disease epidemiology at University College London and a member of the Scientific Advisory Group for Emergencies, said a "sustainable strategy" will be needed in the future to tackle coronavirus mutations.

He said that, while it is sensible to try to stamp out chains of transmission of variants, new strains will continue to be a risk and suggested borders cannot stay shut forever.

Asked on Sky News about the probability of more strains entering the UK unless borders are closed completely, or unless all people entering the country are forced into hotel quarantine for 14 days, Hayward said: "Well, probably in the long term, 100%.

"The nature of this virus is that it will continue to mutate, as do all viruses, and new strains will emerge and they'll emerge in many different countries in the world at different times, and you won't notice that they are spreading until such time as they are quite widespread.

"The real challenge here is that, well, yes, you can think about completely shutting the borders or having quarantine, (but) what's the endgame in that?

"Is that something that you're going to do forever, because it looks like these strains may continue to arise in the long term?

"So we need some sort of sustainable strategy, and I think that's very difficult for politicians to think about that."

source: PA

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more
25 Apr 2024 08:38

AstraZeneca blows past analysts' estimates for Q1

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more
25 Apr 2024 07:56

REPEAT: Miner Anglo American reviews takeover bid from rival BHP

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 07:52

Sanofi profit slips on generic competition and currency effects

April 25 (Reuters) - Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.